A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Part of paid clinical trials in Orange, California.
- Sponsor
- Sandoz
- Study ID
- NCT06153238
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- GME751 — DRUG400 mg Q6W, i.v. infusion, over 24 weeks period
- Keytruda - EU — DRUG400 mg Q6W, i.v. infusion, over 24 weeks period
- Keytruda - US — DRUG400 mg Q6W, i.v. infusion, over 24 weeks period
Study Details
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in subjects with resected advanced melanoma requiring adjuvant treatment with pembrolizumab.
Key Dates
- Start date
- May 15, 2024
- Status verified
- May 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 322 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: GME751Subjects will receive GME751 via intravenous (IV) infusion.
- Active Comparator: Keytruda - EUSubjects will receive Keytruda-EU via intravenous (IV) infusion.
- Active Comparator: Keytruda - USSubjects will receive Keytruda-US via intravenous (IV) infusion.
Primary Outcome Measure
Area Under the Serum Concentration-time Curve from Time Zero to 42 Days (AUC0-42d) [ Time Frame: Day 1 (Postdose) through Day 42 ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sandoz Investigational Site | Orange | California | 92868 | - |
| Sandoz Investigational Site | Clermont | Florida | 34711 | - |
| Sandoz Investigational Site | Orange City | Florida | 32763 | - |
Find similar trials in Orange, CA
By condition
By specialty
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPHASE2 · Recruiting · Vyriad, Inc. · Phoenix, Arizona
- Nodal Radiation Therapy for Sentinel Lymph Node Positive MelanomaPHASE2 · Recruiting · M.D. Anderson Cancer Center · Jacksonville, Florida